The phosphorylation of α-synuclein: Development and implication for the mechanism and therapy of the Parkinson's disease

Journal of Neurochemistry

Volumn 135, Issue 1, 2015, Pages 4-18

  Xu, Yan ^a   Deng, Yulin ^a   Qing, Hong ^a  

^a BEIJING INSTITUTE OF TECHNOLOGY   (China)

Author keywords

neurotoxicity; Parkinson's disease; synuclein phosphorylation

Indexed keywords

ALPHA SYNUCLEIN; BIOLOGICAL MARKER; SERINE; TYROSINE; NERVE PROTEIN;

AMINO ACID ANALYSIS; AMINO ACID SEQUENCE; HUMAN; LEWY BODY; MUTATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BRAIN; METABOLISM; NERVE CELL; PHOSPHORYLATION;

ALPHA-SYNUCLEIN; ANIMALS; BRAIN; HUMANS; NERVE TISSUE PROTEINS; NEURONS; PARKINSON DISEASE; PHOSPHORYLATION;

EID: 84942499950     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13234     Document Type: Review

References (109)

1. Abeliovich A., Schmitz Y., Farinas I., et al., (2000) Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25, 239-252.
2. Ahn B. H., Rhim H., Kim S. Y., et al., (2002) alpha-Synuclein interacts with phospholipase D isozymes and inhibits pervanadate-induced phospholipase D activation in human embryonic kidney-293 cells. J. Biol. Chem. 277, 12334-12342.
3. Alim M. A., Ma Q. L., Takeda K., et al., (2004) Demonstration of a role for alpha-synuclein as a functional microtubule-associated protein. J. Alzheimers Dis. 6, 435-442; discussion 443-439.
4. Anderson J. P., Walker D. E., Goldstein J. M., et al., (2006) Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 281, 29739-29752.
5. Azeredo da Silveira S., Schneider B. L., Cifuentes-Diaz C., Sage D., Abbas-Terki T., Iwatsubo T., Unser M., and, Aebischer P., (2009) Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease. Hum. Mol. Genet. 18, 872-887.
6. Bergeron M., Motter R., Tanaka P., Fauss D., Babcock M., Chiou S. S., Nelson S., San Pablo F., and, Anderson J. P., (2014) In vivo modulation of polo-like kinases supports a key role for PLK2 in Ser129 alpha-synuclein phosphorylation in mouse brain. Neuroscience 256, 72-82.
7. Bi W., Zhang G., Sun Y., Zhu L., Wang C., Liang Y., Shi Q., and, Tao E., (2011) Serine 129 Phosphorylation of alpha-Synuclein Cross-Links with Tissue Transglutaminase to Form Lewy Body-Like Inclusion Bodies. ISRN Neurol. 113, 32-35.
8. Cabin D. E., Shimazu K., Murphy D., et al., (2002) Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J. Neurosci. 22, 8797-8807.
9. Chartier-Harlin M. C., Kachergus J., Roumier C., et al., (2004) Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364, 1167-1169.
10. Chau K. Y., Ching H. L., Schapira A. H., and, Cooper J. M., (2009) Relationship between alpha synuclein phosphorylation, proteasomal inhibition and cell death: relevance to Parkinson's disease pathogenesis. J. Neurochem. 110, 1005-1013.
11. Chen L., and, Feany M. B., (2005) Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat. Neurosci. 8, 657-663.
12. Chen L., Periquet M., Wang X., Negro A., McLean P. J., Hyman B. T., and, Feany M. B., (2009) Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. J. Clin. Invest. 119, 3257-3265.
13. Choi B. K., Choi M. G., Kim J. Y., Yang Y., Lai Y., Kweon D. H., Lee N. K., and, Shin Y. K., (2013) Large alpha-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking. Proc. Natl Acad. Sci. USA 110, 4087-4092.
14. Colla E., Jensen P. H., Pletnikova O., Troncoso J. C., Glabe C., and, Lee M. K., (2012) Accumulation of toxic alpha-synuclein oligomer within endoplasmic reticulum occurs in alpha-synucleinopathy in vivo. J. Neurosci. 32, 3301-3305.
15. Conway K. A., Harper J. D., and, Lansbury P. T., (1998) Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med. 4, 1318-1320.
16. Conway K. A., Lee S. J., Rochet J. C., Ding T. T., Harper J. D., Williamson R. E., and, Lansbury P. T. Jr., (2000) Accelerated oligomerization by Parkinson's disease linked alpha-synuclein mutants. Ann. N. Y. Acad. Sci. 920, 42-45.
17. Conway K. A., Rochet J. C., Bieganski R. M., and, Lansbury P. T. Jr., (2001) Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294, 1346-1349.
18. Corbit K. C., Trakul N., Eves E. M., Diaz B., Marshall M., and, Rosner M. R., (2003) Activation of Raf-1 signaling by protein kinase C through a mechanism involving Raf kinase inhibitory protein. J. Biol. Chem. 278, 13061-13068.
19. Cuervo A. M., Stefanis L., Fredenburg R., Lansbury P. T., and, Sulzer D., (2004) Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305, 1292-1295.
20. Ebrahimi-Fakhari D., Cantuti-Castelvetri I., Fan Z., Rockenstein E., Masliah E., Hyman B. T., McLean P. J., and, Unni V. K., (2011) Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of alpha-synuclein. J. Neurosci. 31, 14508-14520.
21. El-Agnaf O. M., Jakes R., Curran M. D., Middleton D., Ingenito R., Bianchi E., Pessi A., Neill D., and, Wallace A., (1998a) Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments. FEBS Lett. 440, 71-75.
22. El-Agnaf O. M., Jakes R., Curran M. D., and, Wallace A., (1998b) Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease. FEBS Lett. 440, 67-70.
23. Eliezer D., Kutluay E., Bussell R., Jr, and, Browne G., (2001) Conformational properties of alpha-synuclein in its free and lipid-associated states. J. Mol. Biol. 307, 1061-1073.
24. Ellis C. E., Schwartzberg P. L., Grider T. L., Fink D. W., and, Nussbaum R. L., (2001) alpha-synuclein is phosphorylated by members of the Src family of protein-tyrosine kinases. J. Biol. Chem. 276, 3879-3884.
25. Escobar V. D., Kuo Y. M., Orrison B. M., Giasson B. I., and, Nussbaum R. L., (2014) Transgenic mice expressing S129 phosphorylation mutations in alpha-synuclein. Neurosci. Lett. 563, 96-100.
26. Esteves A. R., Swerdlow R. H., and, Cardoso S. M., (2014) LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesis. Exp. Neurol. 261C, 206-216.
27. Febbraro F., Sahin G., Farran A., Soares S., Jensen P. H., Kirik D., and, Romero-Ramos M., (2013) Ser129D mutant alpha-synuclein induces earlier motor dysfunction while S129A results in distinctive pathology in a rat model of Parkinson's disease. Neurobiol. Dis. 56, 47-58.
28. Foulds P. G., Mitchell J. D., Parker A., Turner R., Green G., Diggle P., Hasegawa M., Taylor M., Mann D., and, Allsop D., (2011) Phosphorylated alpha-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease. FASEB J. 25, 4127-4137.
29. Fujiwara H., Hasegawa M., Dohmae N., Kawashima A., Masliah E., Goldberg M. S., Shen J., Takio K., and, Iwatsubo T., (2002) alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4, 160-164.
30. Giasson B. I., Murray I. V., Trojanowski J. Q., and, Lee V. M., (2001) A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J. Biol. Chem. 276, 2380-2386.
31. Giehm L., Svergun D. I., Otzen D. E., and, Vestergaard B., (2011) Low-resolution structure of a vesicle disrupting α-synuclein oligomer that accumulates during fibrillation. Proc. Natl Acad. Sci. USA 108, 3246-3251.
32. Gorbatyuk O. S., Li S., Sullivan L. F., Chen W., Kondrikova G., Manfredsson F. P., Mandel R. J., and, Muzyczka N., (2008) The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease. Proc. Natl Acad. Sci. USA 105, 763-768.
33. Hara S., Arawaka S., Sato H., Machiya Y., Cui C., Sasaki A., Koyama S., and, Kato T., (2013) Serine 129 phosphorylation of membrane-associated alpha-synuclein modulates dopamine transporter function in a G protein-coupled receptor kinase-dependent manner. Mol. Biol. Cell 24 (1649-1660), S1641-S1643.
34. Hashimoto M., Hsu L. J., Xia Y., Takeda A., Sisk A., Sundsmo M., and, Masliah E., (1999) Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. NeuroReport 10, 717-721.
35. Hashimoto M., Kawahara K., Bar-On P., Rockenstein E., Crews L., and, Masliah E., (2004) The Role of alpha-synuclein assembly and metabolism in the pathogenesis of Lewy body disease. J. Mol. Neurosci. 24, 343-352.
36. Hejjaoui M., Butterfield S., Fauvet B., et al., (2012) Elucidating the role of C-terminal post-translational modifications using protein semisynthesis strategies: alpha-synuclein phosphorylation at tyrosine 125. J. Am. Chem. Soc. 134, 5196-5210.
37. Hsu L. J., Sagara Y., Arroyo A., Rockenstein E., Sisk A., Mallory M., Wong J., Takenouchi T., Hashimoto M., and, Masliah E., (2000) alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am. J. Pathol. 157, 401-410.
38. Inglis K. J., Chereau D., Brigham E. F., et al., (2009) Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system. J. Biol. Chem. 284, 2598-2602.
39. Irwin D. J., Lee V. M., and, Trojanowski J. Q., (2013) Parkinson's disease dementia: convergence of alpha-synuclein, tau and amyloid-beta pathologies. Nat. Rev. Neurosci. 14, 626-636.
40. Iwai A., Masliah E., Yoshimoto M., Ge N., Flanagan L., de Silva H. A., Kittel A., and, Saitoh T., (1995) The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14, 467-475.
41. Iwatsubo T., (2007) Pathological biochemistry of alpha-synucleinopathy. Neuropathology 27, 474-478.
42. Kim E. J., Sung J. Y., Lee H. J., Rhim H., Hasegawa M., Iwatsubo T., Min do S., Kim J., Paik S. R., and, Chung K. C., (2006) Dyrk1A phosphorylates alpha-synuclein and enhances intracellular inclusion formation. J. Biol. Chem. 281, 33250-33257.
43. Kosten J., Binolfi A., Stuiver M., Verzini S., Theillet F. X., Bekei B., van Rossum M., and, Selenko P., (2014) Efficient modification of alpha-synuclein serine 129 by protein kinase CK1 requires phosphorylation of tyrosine 125 as a priming event. ACS Chem. Neurosci. 5, 1203-1208.
44. Kragh C. L., Ubhi K., Wyss-Coray T., and, Masliah E., (2012) Autophagy in dementias. Brain Pathol. 22, 99-109.
45. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J. T., Schols L., and, Riess O., (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18, 106-108.
46. Kuwahara T., Tonegawa R., Ito G., Mitani S., and, Iwatsubo T., (2012) Phosphorylation of alpha-synuclein protein at Ser-129 reduces neuronal dysfunction by lowering its membrane binding property in Caenorhabditis elegans. J. Biol. Chem. 287, 7098-7109.
47. Lashuel H. A., Overk C. R., Oueslati A., and, Masliah E., (2013) The many faces of alpha-synuclein: from structure and toxicity to therapeutic target. Nat. Rev. Neurosci. 14, 38-48.
48. de Lau L. M., Koudstaal P. J., Hofman A., and, Breteler M. M., (2006) Subjective complaints precede Parkinson disease: the rotterdam study. Arch. Neurol. 63, 362-365.
49. Lee V. M., and, Trojanowski J. Q., (2006) Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery. Neuron 52, 33-38.
50. Leger J., Kempf M., Lee G., and, Brandt R., (1997) Conversion of serine to aspartate imitates phosphorylation-induced changes in the structure and function of microtubule-associated protein tau. J. Biol. Chem. 272, 8441-8446.
51. Lu Y., Prudent M., Fauvet B., Lashuel H. A., and, Girault H. H., (2011) Phosphorylation of alpha-Synuclein at Y125 and S129 alters its metal binding properties: implications for understanding the role of alpha-Synuclein in the pathogenesis of Parkinson's Disease and related disorders. ACS Chem. Neurosci. 2, 667-675.
52. Luk K. C., Song C., O'Brien P., Stieber A., Branch J. R., Brunden K. R., Trojanowski J. Q., and, Lee V. M., (2009) Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc. Natl Acad. Sci. USA 106, 20051-20056.
53. Lundblad M., Decressac M., Mattsson B., and, Bjorklund A., (2012) Impaired neurotransmission caused by overexpression of alpha-synuclein in nigral dopamine neurons. Proc. Natl Acad. Sci. USA 109, 3213-3219.
54. Mbefo M. K., Paleologou K. E., Boucharaba A., et al., (2010) Phosphorylation of synucleins by members of the Polo-like kinase family. J. Biol. Chem. 285, 2807-2822.
55. McCormack A. L., Mak S. K., and, Di Monte D. A., (2012) Increased alpha-synuclein phosphorylation and nitration in the aging primate substantia nigra. Cell Death Dis. 3, e315.
56. McFarland M. A., Ellis C. E., Markey S. P., and, Nussbaum R. L., (2008) Proteomics analysis identifies phosphorylation-dependent alpha-synuclein protein interactions. Mol. Cell Proteomics 7, 2123-2137.
57. McFarland N. R., Fan Z., Xu K., Schwarzschild M. A., Feany M. B., Hyman B. T., and, McLean P. J., (2009) Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease. J. Neuropathol. Exp. Neurol. 68, 515-524.
58. Mollenhauer B., Cullen V., Kahn I., et al., (2008) Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp. Neurol. 213, 315-325.
59. Muntane G., Dalfo E., Martinez A., and, Ferrer I., (2008) Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related alpha-synucleinopathies. Neuroscience 152, 913-923.
60. Nakamura T., Yamashita H., Takahashi T., and, Nakamura S., (2001) Activated Fyn phosphorylates alpha-synuclein at tyrosine residue 125. Biochem. Biophys. Res. Commun. 280, 1085-1092.
61. Negro A., Brunati A. M., Donella-Deana A., Massimino M. L., and, Pinna L. A., (2002) Multiple phosphorylation of alpha-synuclein by protein tyrosine kinase Syk prevents eosin-induced aggregation. FASEB J. 16, 210-212.
62. Nemani V. M., Lu W., Berge V., Nakamura K., Onoa B., Lee M. K., Chaudhry F. A., Nicoll R. A., and, Edwards R. H., (2010) Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65, 66-79.
63. Nubling G. S., Levin J., Bader B., Lorenzl S., Hillmer A., Hogen T., Kamp F., and, Giese A., (2014) Modelling Ser129 phosphorylation inhibits membrane binding of pore-forming alpha-synuclein oligomers. PLoS ONE 9, e98906.
64. Ohrfelt A., Grognet P., Andreasen N., Wallin A., Vanmechelen E., Blennow K., and, Zetterberg H., (2009) Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci. Lett. 450, 332-335.
65. Okochi M., Walter J., Koyama A., Nakajo S., Baba M., Iwatsubo T., Meijer L., Kahle P. J., and, Haass C., (2000) Constitutive Phosphorylation of the Parkinson's Disease Associated α-Synuclein. J. Biol. Chem. 275, 390-397.
66. Oueslati A., Fournier M., and, Lashuel H. A., (2010) Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies. Prog. Brain Res. 183, 115-145.
67. Oueslati A., Paleologou K. E., Schneider B. L., Aebischer P., and, Lashuel H. A., (2012) Mimicking phosphorylation at serine 87 inhibits the aggregation of human alpha-synuclein and protects against its toxicity in a rat model of Parkinson's disease. J. Neurosci. 32, 1536-1544.
68. Paleologou K. E., Schmid A. W., Rospigliosi C. C., et al., (2008) Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein. J. Biol. Chem. 283, 16895-16905.
69. Paleologou K. E., Oueslati A., Shakked G., et al., (2010) Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions. J. Neurosci. 30, 3184-3198.
70. Perfeito R., Lazaro D. F., Outeiro T. F., and, Rego A. C., (2014) Linking alpha-synuclein phosphorylation to reactive oxygen species formation and mitochondrial dysfunction in SH-SY5Y cells. Mol. Cell Neurosci. 62C, 51-59.
71. Poehler A. M., Xiang W., Spitzer P., et al., (2014) Autophagy modulates SNCA/alpha-synuclein release, thereby generating a hostile microenvironment. Autophagy, 10, 2171-2192.
72. Polymeropoulos M. H., Lavedan C., Leroy E., et al., (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047.
73. Pronin A. N., Morris A. J., Surguchov A., and, Benovic J. L., (2000) Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J. Biol. Chem. 275, 26515-26522.
74. Qing H., Wong W., McGeer E. G., and, McGeer P. L., (2009) Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications. Biochem. Biophys. Res. Commun. 387, 149-152.
75. Ramakrishnan M., Jensen P. H., and, Marsh D., (2006) Association of alpha-synuclein and mutants with lipid membranes: spin-label ESR and polarized IR. Biochemistry 45, 3386-3395.
76. Richards J. P., Bachinger H. P., Goodman R. H., and, Brennan R. G., (1996) Analysis of the structural properties of cAMP-responsive element-binding protein (CREB) and phosphorylated CREB. J. Biol. Chem. 271, 13716-13723.
77. Sancenon V., Lee S. A., Patrick C., Griffith J., Paulino A., Outeiro T. F., Reggiori F., Masliah E., and, Muchowski P. J., (2012) Suppression of alpha-synuclein toxicity and vesicle trafficking defects by phosphorylation at S129 in yeast depends on genetic context. Hum. Mol. Genet. 21, 2432-2449.
78. Schapira A. H., (1999) Science, medicine, and the future: Parkinson's disease. BMJ 318, 311-314.
79. Scott D. A., Tabarean I., Tang Y., Cartier A., Masliah E., and, Roy S., (2010) A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration. J. Neurosci. 30, 8083-8095.
80. Seidel K., Schols L., Nuber S., et al., (2010) First appraisal of brain pathology owing to A30P mutant alpha-synuclein. Ann. Neurol. 67, 684-689.
81. Sharon R., Bar-Joseph I., Frosch M. P., Walsh D. M., Hamilton J. A., and, Selkoe D. J., (2003) The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 37, 583-595.
82. Smith W. W., Margolis R. L., Li X., Troncoso J. C., Lee M. K., Dawson V. L., Dawson T. M., Iwatsubo T., and, Ross C. A., (2005) Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. J. Neurosci. 25, 5544-5552.
83. Souza J. M., Giasson B. I., Chen Q., Lee V. M., and, Ischiropoulos H., (2000) Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J. Biol. Chem. 275, 18344-18349.
84. Spencer B., Potkar R., Trejo M., Rockenstein E., Patrick C., Gindi R., Adame A., Wyss-Coray T., and, Masliah E., (2009) Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases. J. Neurosci. 29, 13578-13588.
85. Spillantini M. G., Schmidt M. L., Lee V. M., Trojanowski J. Q., Jakes R., and, Goedert M., (1997) Alpha-synuclein in Lewy bodies. Nature 388, 839-840.
86. Sugeno N., Takeda A., Hasegawa T., Kobayashi M., Kikuchi A., Mori F., Wakabayashi K., and, Itoyama Y., (2008) Serine 129 phosphorylation of alpha-synuclein induces unfolded protein response-mediated cell death. J. Biol. Chem. 283, 23179-23188.
87. Takahashi M., Kanuka H., Fujiwara H., Koyama A., Hasegawa M., Miura M., and, Iwatsubo T., (2003a) Phosphorylation of alpha-synuclein characteristic of synucleinopathy lesions is recapitulated in alpha-synuclein transgenic Drosophila. Neurosci. Lett. 336, 155-158.
88. Takahashi T., Yamashita H., Nagano Y., Nakamura T., Ohmori H., Avraham H., Avraham S., Yasuda M., and, Matsumoto M., (2003b) Identification and characterization of a novel Pyk2/related adhesion focal tyrosine kinase-associated protein that inhibits alpha-synuclein phosphorylation. J. Biol. Chem. 278, 42225-42233.
89. Takahashi M., Ko L. W., Kulathingal J., Jiang P., Sevlever D., and, Yen S. H., (2007) Oxidative stress-induced phosphorylation, degradation and aggregation of alpha-synuclein are linked to upregulated CK2 and cathepsin D. Eur. J. Neurosci. 26, 863-874.
90. Tenreiro S., Reimao-Pinto M. M., Antas P., et al., (2014) Phosphorylation modulates clearance of alpha-synuclein inclusions in a yeast model of Parkinson's disease. PLoS Genet. 10, e1004302.
91. Tokuda T., Salem S. A., Allsop D., Mizuno T., Nakagawa M., Qureshi M. M., Locascio J. J., Schlossmacher M. G., and, El-Agnaf O. M., (2006) Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem. Biophys. Res. Commun. 349, 162-166.
92. Ueda K., Fukushima H., Masliah E., Xia Y., Iwai A., Yoshimoto M., Otero D. A., Kondo J., Ihara Y., and, Saitoh T., (1993) Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl Acad. Sci. USA 90, 11282-11286.
93. Ullman O., Fisher C. K., and, Stultz C. M., (2011) Explaining the structural plasticity of alpha-synuclein. J. Am. Chem. Soc. 133, 19536-19546.
94. Ulmer T. S., Bax A., Cole N. B., and, Nussbaum R. L., (2005) Structure and dynamics of micelle-bound human alpha-synuclein. J. Biol. Chem. 280, 9595-9603.
95. Uversky V. N., Li J., and, Fink A. L., (2001) Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J. Biol. Chem. 276, 44284-44296.
96. Visanji N. P., Wislet-Gendebien S., Oschipok L. W., Zhang G., Aubert I., Fraser P. E., and, Tandon A., (2011) Effect of Ser-129 phosphorylation on interaction of alpha-synuclein with synaptic and cellular membranes. J. Biol. Chem. 286, 35863-35873.
97. Wang Y., Shi M., Chung K. A., et al., (2012) Phosphorylated alpha-synuclein in Parkinson's disease. Sci. Transl. Med. 4, 121ra120.
98. Waxman E. A., and, Giasson B. I., (2008) Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein. J. Neuropathol. Exp. Neurol. 67, 402-416.
99. Waxman E. A., and, Giasson B. I., (2011) Characterization of kinases involved in the phosphorylation of aggregated alpha-synuclein. J. Neurosci. Res. 89, 231-247.
100. Webb J. L., Ravikumar B., Atkins J., Skepper J. N., and, Rubinsztein D. C., (2003) Alpha-Synuclein is degraded by both autophagy and the proteasome. J. Biol. Chem. 278, 25009-25013.
101. Weinreb P. H., Zhen W., Poon A. W., Conway K. A., and, Lansbury P. T. Jr., (1996) NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 35, 13709-13715.
102. Wu B., Liu Q., Duan C., Li Y., Yu S., Chan P., Ueda K., and, Yang H., (2011) Phosphorylation of alpha-synuclein upregulates tyrosine hydroxylase activity in MN9D cells. Acta Histochem. 113, 32-35.
103. Yamada M., Iwatsubo T., Mizuno Y., and, Mochizuki H., (2004) Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease. J. Neurochem. 91, 451-461.
104. Yin G., Lopes da Fonseca T., Eisbach S. E., et al., (2014) alpha-Synuclein interacts with the switch region of Rab8a in a Ser129 phosphorylation-dependent manner. Neurobiol. Dis. 70, 149-161.
105. Zabrocki P., Bastiaens I., Delay C., Bammens T., Ghillebert R., Pellens K., De Virgilio C., Van Leuven F., and, Winderickx J., (2008) Phosphorylation, lipid raft interaction and traffic of alpha-synuclein in a yeast model for Parkinson. Biochim. Biophys. Acta 1783, 1767-1780.
106. Zarranz J. J., Alegre J., Gomez-Esteban J. C., et al., (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55, 164-173.
107. Zhang L., Zhang C., Zhu Y., Cai Q., Chan P., Ueda K., Yu S., and, Yang H., (2008) Semi-quantitative analysis of alpha-synuclein in subcellular pools of rat brain neurons: an immunogold electron microscopic study using a C-terminal specific monoclonal antibody. Brain Res. 1244, 40-52.
108. Zhou J., Broe M., Huang Y., et al., (2011) Changes in the solubility and phosphorylation of alpha-synuclein over the course of Parkinson's disease. Acta Neuropathol. 121, 695-704.
109. Zhou J. X., Zhang H. B., Huang Y., et al., (2013) Tenuigenin attenuates alpha-synuclein-induced cytotoxicity by down-regulating polo-like kinase 3. CNS Neurosci. Ther. 19, 688-694.